Načítá se...
Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
BACKGROUND: Immune checkpoint inhibitors are effective therapies for a wide range of malignancies. Their increased use has led to a wide range of immune-related adverse effects including skin, gastrointestinal, pulmonary, endocrine, cardiac, and neurologic complications. CASE PRESENTATION: We presen...
Uloženo v:
| Vydáno v: | J Med Case Rep |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8165972/ https://ncbi.nlm.nih.gov/pubmed/34053457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13256-021-02858-7 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|